Palmitoyl Dipeptide-6
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A palmitoylated dipeptide marketed in anti-aging serums to firm skin, smooth crow's feet, and rebuild the dermal-epidermal junction. Evidence is almost entirely mechanistic and in vitro; human proof of real wrinkle or firmness improvement is speculative. The palmitoyl chain aids penetration, not efficacy. Safety data are limited, and excipient allergy is a real, moderate risk. It is a cosmetic ingredient, not an FDA-approved drug, subject to FDA cosmetic requirements.
Read Full recordStudied uses & evidence
Studied uses(5)
Stimulation of dermal-epidermal junction (DEJ) structural proteins (Collagen IV, VII, XVII, Laminin V, Integrin beta-4)
SpeculativeA related lipopeptide raised laminin and collagen IV/XVII in skin cells; this molecule is untested.
Reduction in fine lines and wrinkles, particularly periorbital crow's feet
SpeculativeNo published trials; wrinkle claims come from unpublished, multi-ingredient manufacturer testing.
Improved skin firmness, compactness, and elasticity
SpeculativeInferred from proposed matrix protein effects; no human elasticity or firmness data exist.
Evidence limits
- Evidence Level
- Preclinical
Clinical evidence for Palmitoyl Dipeptide-6 is limited to manufacturer-sponsored cosmetic evaluations and small studies of other peptides. No independent, large-scale, randomized, placebo-controlled clinical trials have been published specifically for this ingredient. The DSM SYN-TACKS clinical program tested the peptide combination at 1% concentration over 56-84 days and reported improvements in skin compactness, wrinkle reduction, and tonicity, but detailed methodology, sample sizes, and statistics are available only in proprietary brochures rather than peer-reviewed publications. Published studies of the distinct palmitoyl-KVK-L-ascorbic acid conjugate (PMID 28303328) and of a different complex of biotinylated and ascorbyl-linked peptides (PMID 31861912) reported wrinkle improvement in small human trials (n=22-32), but they tested different ingredients. CIR deferred the broad 2013 assessment for regrouping; it did not establish this ingredient's safety.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Contact dermatitis or skin irritation (theoretical)
LowLimited long-term safety data
LowAllergic reaction to formulation excipients
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.